Inflammatory Bowel Disease - Healing Genes

Inflammatory Bowel Disease

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease (ADcSVF-IBD)

Use of Autologous Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease

Phase 1/2


Researchers at Regenevita are recruiting patients with IBD for a clinical trial of an investigatory regenerative cell therapy utilizing adipose-derived (from the fat tissue) cells and tissues called stromal vascular fraction (ADcSVF). The treatment will require liposuction to aspirate the ADcSVF from the patient, then it will be processed and concentrated in a lab before being re-administered intravenously.

Patients will be followed for up to a year after treatment, with lab and physical assessments as well as questionnaires.


  • Be 18 to 85 years of age
  • Have a confirmed diagnosis of IBD at least 6 months prior to therapy
  • Have negative pregnancy test for women of childbearing age (menarche to menopause), and not breastfeeding


  1. Prescreening tests to confirm eligibility of the patient to participate.
  2. Liposuction recovery of adipose aspirate for cellular and tissue stromal vascular fraction. There will be lab prep time for these components.
  3. Infusion intravenously of the ADcSVF.
  4. Follow up will continue with physical assessments ~12 months after treatment.


Trials will take place at Regenevita in Stevensville, MT (Map).



Robert W Alexander, MD,  |  4067774477  |  [email protected]

Nancy Smith, MA, ORT  |  4067774477  |  [email protected]




Healeon Medical Inc

Terry, Glenn C., M.D.



Or go online:



Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader